{
  "extraction_metadata": {
    "timestamp": "2025-10-01T17:09:05.936125",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 11,
    "total_picos": 52,
    "temperature": 0.3
  },
  "picos_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "PICOs": [
        {
          "Population": "HCCP patients with Child-Pugh stage A and BC or BLC, with remote tumor measurements or localization that cannot be re-regionised or resected",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab and bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "HCCP patients with Child-Pugh stage A and BC or BLC, with remote tumor measurements or localization that cannot be re-regionised or resected",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "durumavalumab plus tremelimumab",
          "Outcomes": ""
        },
        {
          "Population": "Patients with contraindications for A+B and D+T",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "one of the two tyrosine kinase biliary carcinomas",
          "Outcomes": ""
        },
        {
          "Population": "individual Child Pugh Stage B HCC patients (up to 8 points), with long-term metastasis or tumour localization that is not locally monitored or resectable, and an ECOG status of 0 - 1",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "immunotherapy with an anti-PD-1 antibody",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 8426
    },
    "BE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "BE",
      "PICOs": [
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "arterial chemoembolization",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "radioactive Iodine 131 treatment",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "systemic chemotherapy (doxorubicin or cisplatin)",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "hormonal therapy with tamoxifen",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "octreotide",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 8281
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "conventional TACE",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "drug-eluting bead TACE",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "transarterial radio-embolization (TARE)",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best supportive care",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 8542
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "PICOs": [
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma with preserved hepatic function and in good general condition where resection, transplantation, ablation or TACE/SIRT cannot be performed or are not expected to have an effect, or for patients with additional hepatic disease",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab and bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma with preserved hepatic function and in good general condition where resection, transplantation, ablation or TACE/SIRT cannot be performed or are not expected to have an effect, or for patients with additional hepatic disease",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma with preserved hepatic function and in good general condition where resection, transplantation, ablation or TACE/SIRT cannot be performed or are not expected to have an effect, or for patients with additional hepatic disease",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma with preserved hepatic function who have tolerated and subsequently progressed to second-line therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "regorafenib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 8869
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "PICOs": [
        {
          "Population": "advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child–Pugh class A",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "BSC",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 17,
      "ContextTokens": 5125
    },
    "EU": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EU",
      "PICOs": [],
      "ChunksUsed": 6,
      "ContextTokens": 2666
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "PICOs": [
        {
          "Population": "patients with compensated cirrhosis (Child-Pugh score A), in good general condition (PS 0-2), and advanced HCC (BCLC C or B not eligible for TACE)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with compensated cirrhosis (Child-Pugh score A), in good general condition (PS 0-2), and advanced HCC (BCLC C or B not eligible for TACE)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced HCC previously treated with sorafenib",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "regorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced HCC previously treated with sorafenib",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "cabozantinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (AFP > 400 ng/mL) after sorafenib",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "ramucirumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced hepatocellular carcinoma previously treated with sorafenib",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nivolumab plus ipilimumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced hepatocellular carcinoma with portal vein thrombosis, in good PS, Child-Pugh A and ineligible (or after failure) to sorafenib",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "SIRT with Therasphere",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 9620
    },
    "IT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "IT",
      "PICOs": [
        {
          "Population": "patients with advanced HCC who have failed or are not eligible for local-regional therapy, with impaired hepatic function (Child-Pugh B)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced HCC and Child-Pugh B liver cirrhosis",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced HCC and Child-Pugh C liver cirrhosis",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best supportive therapy",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced stage of HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "FOLFOX4",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced stage of HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "doxorubicin",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced HCC, not eligible for any loco-regional treatment (either at diagnosis or after failure of any previous treatments), with good liver function (Child-Pugh)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 9155
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "PICOs": [
        {
          "Population": "patients with (locally) advanced hepatocellular carcinoma, where no resection, ablation or TACE is possible",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Transarterial radioembolization (TARE)",
          "Outcomes": ""
        },
        {
          "Population": "patients with (locally) advanced hepatocellular carcinoma, where no resection, ablation or TACE is possible",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with (locally) advanced hepatocellular carcinoma, where no resection, ablation or TACE is possible",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab plus bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with (locally) advanced hepatocellular carcinoma, where no resection, ablation or TACE is possible",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 7502
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "PICOs": [
        {
          "Population": "patients with non-surgical hepatocellular carcinoma in good general condition and with good liver function (Child and Pugha Class A)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "combination of bevacizumab and atezolizumab",
          "Outcomes": ""
        },
        {
          "Population": "patients previously treated with Sorafenib with AFP ≥ 400 ng/ ml",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "ramucyrumab",
          "Outcomes": ""
        },
        {
          "Population": "patients who have previously received bevacizumab with atezolizumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients who have previously received bevacizumab with atezolizumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "leninivat",
          "Outcomes": ""
        },
        {
          "Population": "patients who have previously received bevacizumab with atezolizumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "cabozantinib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 12,
      "ContextTokens": 3639
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "PICOs": [
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab and bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) when combination therapy is inappropriate",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "tremelimumab-durvalumab combination",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma following progression on first line treatment with tyrosine kinase inhibitor",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "regorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma following progression on first line treatment with tyrosine kinase inhibitor",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "cabozantinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma following progression on first line treatment with tyrosine kinase inhibitor",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "ramucirumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma after first line treatment with atezolizumab-bevacizumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma after first line treatment with atezolizumab-bevacizumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma after first line treatment with atezolizumab-bevacizumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "regorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma after first line treatment with atezolizumab-bevacizumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "cabozantinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma after first line treatment with atezolizumab-bevacizumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "ramucirumab",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 8362
    }
  }
}